Skip to main content
Premium Trial:

Request an Annual Quote

Arrayit Diagnostics Licenses Ovarian Cancer Biomarkers from Wayne State U

NEW YORK (GenomeWeb News) – Arrayit Diagnostics said today that it has exclusively licensed ovarian cancer biomarker intellectual property from Wayne State University.

Under the agreement, Houston-based Arrayit Diagnostics, a majority-owned subsidiary of Sunnyvale, Calif.-based Arrayit Corporation, gains exclusive worldwide rights to develop and commercialize a microarray-based diagnostic test using the biomarkers, which were developed by WSU researchers Michael Tainsky, Sorin Draghici, and Madhumita Chatterjee.

The test aims to effectively screen for early-stage ovarian cancer in women who are not yet symptomatic, addressing the fact that the disease often presents with largely non-specific symptoms during its initial stages, and is diagnosed only when later-stage symptoms manifest and the disease has metastasized to other parts of the body, Arrayit said.

Arrayit said that it plans to file a pre-market approval application for its diagnostic test with the US Food and Drug Administration in the "near future." If the test kit is approved, Arrayit Diagnostics will market and distribute it worldwide, the company said.

Financial terms of the agreement with WSU were not disclosed.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.